文献速递消化系统肿瘤

基于ABC因素的局限性胰腺癌改进临床分期系统:TAPS联盟研究

Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study.
PubMed 文献 · J Clin Oncol · 2024-02-05

该回顾性队列研究纳入美国和荷兰五个高容量胰腺癌中心2012至2019年接受初始(m)FOLFIRINOX治疗的1835例局限性胰腺导管腺癌患者,多变量Cox分析显示可切除性、CA 19-9和体力状况均为总生存的独立预后因素,据此构建ABC评分并显示评分0至4分的中位总生存依次降低。

要点

  • BR疾病、LA疾病、CA 19-9>500 U/mL和WHO体力状况≥1均为总生存的独立不良预后因素。
  • ABC评分每项不良因素计1分,LA疾病计2分,评分0至4分中位总生存分别为49.7、29.9、22.0、19.1和14.9个月。
  • 作者认为局限性胰腺导管腺癌诊断时的分期应基于解剖、CA 19-9和体力状况。

核心结论

  • 肿瘤解剖、CA 19-9和体力状况(ABC因素)是接受初始(m)FOLFIRINOX治疗的局限性胰腺导管腺癌患者总生存的独立预后因素。
  • 作者认为局限性胰腺导管腺癌诊断时的分期应基于解剖、CA 19-9和体力状况。

研究设计与样本

  • 回顾性队列研究,纳入美国和荷兰五个高容量胰腺癌中心2012至2019年接受初始(m)FOLFIRINOX治疗的局限性胰腺导管腺癌患者1835例。

主要发现

  • 诊断时肿瘤分期为潜在可切除者346例(18.9%),BR者531例(28.9%),LA者958例(52.2%)。
  • 基线CA 19-9>500 U/mL者559例(32.5%),体力状况≥1者1110例(60.7%)。
  • 总生存的独立不良预后因素包括BR疾病(HR 1.26,95%CI 1.06至1.50)、LA疾病(HR 1.71,95%CI 1.45至2.02)、CA 19-9>500 U/mL(HR 1.36,95%CI 1.21至1.52)和WHO体力状况≥1(HR 1.31,95%CI 1.16至1.47)。
  • 评分0、1、2、3、4分患者的中位总生存分别为49.7、29.9、22.0、19.1和14.9个月,相应5年总生存率分别为47.0%、28.9%、19.2%、9.3%和4.8%。

关键数值与推荐

  • 每项不良ABC因素计1分,LA疾病计2分,总评分范围0至4分。

临床怎么用

  • 作者认为局限性胰腺导管腺癌诊断时的分期应基于解剖、CA 19-9和体力状况。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Previous studies suggest that besides anatomy (A: resectable, borderline resectable [BR], or locally advanced [LA]) also biologic (B: carbohydrate antigen 19-9 [CA 19-9]) and conditional (C: performance status) factors should be considered when staging patients with localized pancreatic ductal adenocarcinoma (PDAC). The prognostic value of the combined ABC factors has not been quantitatively validated. METHODS: In this retrospective cohort study, we evaluated patients with localized PDAC treated with initial (modified) fluorouracil with leucovorin, irinotecan, and oxaliplatin ([m]FOLFIRINOX) at five high-volume pancreatic cancer centers in the United States and the Netherlands (2012-2019). Multivariable Cox proportional hazards analysis was used to investigate the impact of the ABC factors for overall survival (OS). RESULTS: Overall, 1,835 patients with localized PDAC were included. Tumor stage at diagnosis was potentially resectable in 346 (18.9%), BR in 531 (28.9%), and LA in 958 (52.2%) patients. The baseline CA 19-9 was >500 U/mL in 559 patients (32.5%). Performance status was ≥1 in 1,110 patients (60.7%). Independent poor prognostic factors for OS were BR disease (hazard ratio [HR], 1.26 [95% CI, 1.06 to 1.50]), LA disease (HR, 1.71 [95% CI, 1.45 to 2.02]), CA 19-9 >500 U/mL (HR, 1.36 [95% CI, 1.21 to 1.52]), and WHO performance status ≥1 (HR, 1.31 [95% CI, 1.16 to 1.47]). Patients were assigned 1 point for each poor ABC factor and 2 points for LA disease. The median OS for patients with score 0-4 was 49.7, 29.9, 22.0, 19.1, and 14.9 months with corresponding 5-year OS rates of 47.0%, 28.9%, 19.2%, 9.3%, and 4.8%, respectively. CONCLUSION: The ABC factors of tumor anatomy, CA 19-9, and performance status at diagnosis were independent prognostic factors for OS in patients with localized PDAC treated with initial (m)FOLFIRINOX. Staging of patients with localized PDAC at diagnosis should be based on anatomy, CA 19-9, and performance status.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Dekker EN, van Dam JL, Janssen QP, et al. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. J Clin Oncol. 2024. PMID: 38315954. doi:10.1200/JCO.23.01311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。